Pharmacogenomics: A focus on antidepressants and atypical antipsychotics.
Ontology highlight
ABSTRACT: The study of pharmacogenomics is rapidly growing, particularly in the field of mental health. Understanding pharmacogenomic principles can be a challenge for many clinicians. Most mental health genomic data concentrates on variability (response, side effects) with antidepressants and atypical antipsychotics. Current pharmacogenomic practice and research primarily focuses on two areas: pharmacodynamics and pharmacokinetics. Based on the current literature, genetic polymorphisms of pharmacodynamics and pharmacokinetics parameters likely influence medication efficacy, therefore affecting the therapeutic benefit. Additionally, certain pharmacodynamic and pharmacokinetic polymorphisms have been linked to an elevated risk of side effects and adverse events with these medications. In this review,
SUBMITTER: Lister JF
PROVIDER: S-EPMC6009243 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA